Reading view
Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma
Nature Medicine, Published online: 17 September 2026; doi:10.1038/s41591-026-04646-6
Results of this study show in experimental models and data from patient cohorts that the antiseizure medication levetiracetam is associated with longer survival and reduced tumor growth in diffuse midline glioma, but not hemispheric high-grade glioma, by selectively dampening GABAergic synaptic signaling, independently of its canonical SV2A-mediated primary antiseizure mechanism.Design Guidelines for Online Health Forums: User-Centered Design Approach
Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers: Molecular Rationale, Clinical Evidence, and Translational Barriers
Int J Mol Sci. 2026 Aug 10;27(16):7155. doi: 10.3390/ijms27167155.
ABSTRACT
Endometrial and cervical cancers can recur from subclinical disease not evident on routine surveillance. This narrative review critically evaluates liquid biopsy for minimal residual disease (MRD) assessment and recurrence monitoring. Post-treatment human papillomavirus (HPV) circulating tumor DNA (ctDNA) in cervical cancer has the strongest disease-specific prospective evidence of clinical validity; persistent detection is strongly associated with recurrence, but moderate sensitivity and false-negative results do not support treatment de-escalation on negativity alone. With regard to endometrial cancer, perioperative ctDNA has prognostic support from an 11-study, 1298-patient meta-analysis and additional cohorts, although assay heterogeneity and limited independent replication constrain clinical readiness. Postoperative positivity generally shows stronger associations than preoperative detection. Cervicovaginal and urine DNA-methylation studies provide preliminary evidence for detecting established recurrence, especially local recurrence, but not prospective molecular lead time or clinical utility. Digital PCR, disease-specific fixed panels, tumor-informed assays, and error-corrected sequencing serve distinct settings; broad pan-cancer plasma profiling remains mainly an advanced-disease tool. Circulating tumor cells, extracellular vesicles, microRNAs, tumor-educated platelets, and fragmentomics remain exploratory. Liquid biopsy should remain an investigational adjunct until prospective trials show that acting on molecular findings improves outcomes.
PMID:42653160 | PMC:PMC13513691 | DOI:10.3390/ijms27167155
PromptAudit: Auditing Prompt Sensitivity in LLM-Based Vulnerability Detection
Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition
A spatial atlas of the healthy human liver from live donors
Nature, Published online: 15 April 2026; doi:10.1038/s41586-026-10377-y
A human spatial atlas of gene expression in liver based on live donors shows marked porto–central zonation of hepatocytes and non-parenchymal cells, and transcriptomic changes in early steatosis.A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
Informatics for Food Processing
Towards Context-Aware Image Anonymization with Multi-Agent Reasoning
The MicrobeAtlas database: Global trends and insights into Earth’s microbial ecosystems
VectorGym: A Multitask Benchmark for SVG Code Generation, Sketching, and Editing
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial
Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04299-5
Results of the phase 2 POLAR trial show that biomarker-guided treatment in patients with metastatic pancreatic cancer based on homologous repair deficiency leads to encouraging clinical response rates in immune cell-infiltrated tumors.Uncharted: understanding women’s health across the body
Nature, Published online: 06 March 2026; doi:10.1038/d41586-026-00526-8
Disaggregating data by sex is a powerful way to help develop better diagnostics and treatments for women — but researchers say it’s not used enough.